SCHEMBL14633730

SCHEMBL14633730

CCOc1cc(-c2cnc(N)nc2Nc2n[nH]c3ccc(F)cc23)cc(S(=O)(=O)CC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 4/20 0.40
MAPK14 Q16539 4/20 0.38
GAK O14976 1/20 0.38
LCK P06239 1/20 0.38
TGFBR1 P36897 1/20 0.38
KCNH2 Q12809 1/20 0.38
RIPK3 Q9Y572 1/20 0.38
TTK P33981 2/20 0.38
MAPK8 P45983 2/20 0.38
JAK2 O60674 1/20 0.37
EGFR P00533 1/20 0.36
FGFR1 P11362 2/20 0.35
FGFR2 P21802 2/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35
FADS1 O60427 1/20 0.34
GSK3A P49840 2/20 0.34
GSK3B P49841 2/20 0.34
TP53 P04637 2/20 0.33
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14633702 0.94 RIPK2 (0.46) RIPK2MAPK14GAKLCKTGFBR1
SCHEMBL2462891 0.93 RIPK2 (0.40) RIPK2MAPK14GAKLCKTGFBR1
SCHEMBL2471579 0.88 RIPK2 (0.39) RIPK2MAPK14GAKLCKTGFBR1
SCHEMBL14634163 0.80 RIPK2 (0.48) RIPK2MAPK14GAKLCKTGFBR1
SCHEMBL2466795 0.78 FADS1 (0.45) RIPK2MAPK14GAKLCKTGFBR1
SCHEMBL2467239 0.78 RIPK2 (0.44) RIPK2MAPK14GAKLCKTGFBR1
SCHEMBL2468419 0.75 ADORA1 (0.46) EGFRFGFR1MAPTPIK3CA
SCHEMBL14634025 0.74 RIPK2 (0.49) RIPK2MAPK14GAKLCKTGFBR1
SCHEMBL2514189 0.72 RIPK2 (0.45) RIPK2MAPK14GAKLCKTGFBR1
SCHEMBL14633552 0.70 GSK3A (0.42) RIPK2MAPK14GAKLCKTGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 RIPK2 443/4885MAPK14 158/4885GAK 237/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 RIPK2 432/4885MAPK14 235/4885GAK 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.